-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
State Board of Administration of Florida Retirement System Makes New $64,000 Investment in Talaris Therapeutics, Inc. (NASDAQ:TALS)
State Board of Administration of Florida Retirement System Makes New $64,000 Investment in Talaris Therapeutics, Inc. (NASDAQ:TALS)
State Board of Administration of Florida Retirement System acquired a new position in Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 14,260 shares of the company's stock, valued at approximately $64,000.
Other hedge funds also recently modified their holdings of the company. Amalgamated Bank bought a new stake in shares of Talaris Therapeutics in the 1st quarter worth approximately $31,000. Prospera Financial Services Inc bought a new stake in shares of Talaris Therapeutics in the 1st quarter worth approximately $50,000. Values First Advisors Inc. bought a new stake in shares of Talaris Therapeutics in the 2nd quarter worth approximately $53,000. JPMorgan Chase & Co. lifted its position in shares of Talaris Therapeutics by 26.3% in the 1st quarter. JPMorgan Chase & Co. now owns 14,826 shares of the company's stock worth $146,000 after acquiring an additional 3,090 shares during the period. Finally, New York State Common Retirement Fund lifted its position in shares of Talaris Therapeutics by 45.2% in the 1st quarter. New York State Common Retirement Fund now owns 14,794 shares of the company's stock worth $146,000 after acquiring an additional 4,605 shares during the period. Institutional investors own 67.99% of the company's stock.
Get Talaris Therapeutics alerts:Talaris Therapeutics Stock Performance
Shares of TALS opened at $1.39 on Wednesday. The stock has a fifty day moving average price of $2.18 and a two-hundred day moving average price of $4.29. Talaris Therapeutics, Inc. has a 52-week low of $1.16 and a 52-week high of $16.63. The company has a market cap of $57.99 million, a price-to-earnings ratio of -0.86 and a beta of 1.94.
Analyst Ratings Changes
Several equities analysts recently commented on the company. Morgan Stanley cut their target price on Talaris Therapeutics from $8.00 to $6.00 and set an "equal weight" rating for the company in a research report on Friday, September 9th. HC Wainwright assumed coverage on Talaris Therapeutics in a research report on Thursday, October 20th. They set a "buy" rating and a $18.00 target price for the company. Finally, Evercore ISI raised their target price on Talaris Therapeutics to $20.00 in a research report on Monday, August 15th.About Talaris Therapeutics
(Get Rating)
Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
Featured Articles
- Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick's Sporting Goods
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
State Board of Administration of Florida Retirement System acquired a new position in Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 14,260 shares of the company's stock, valued at approximately $64,000.
根据佛罗里达州退休系统管理委员会在第二季度收购了Talaris治疗公司(纳斯达克：TALS-GET Rating)的新职位，该公司在最近提交给美国证券交易委员会的文件中称。该公司收购了14,260股该公司的股票，价值约64,000美元。
Other hedge funds also recently modified their holdings of the company. Amalgamated Bank bought a new stake in shares of Talaris Therapeutics in the 1st quarter worth approximately $31,000. Prospera Financial Services Inc bought a new stake in shares of Talaris Therapeutics in the 1st quarter worth approximately $50,000. Values First Advisors Inc. bought a new stake in shares of Talaris Therapeutics in the 2nd quarter worth approximately $53,000. JPMorgan Chase & Co. lifted its position in shares of Talaris Therapeutics by 26.3% in the 1st quarter. JPMorgan Chase & Co. now owns 14,826 shares of the company's stock worth $146,000 after acquiring an additional 3,090 shares during the period. Finally, New York State Common Retirement Fund lifted its position in shares of Talaris Therapeutics by 45.2% in the 1st quarter. New York State Common Retirement Fund now owns 14,794 shares of the company's stock worth $146,000 after acquiring an additional 4,605 shares during the period. Institutional investors own 67.99% of the company's stock.
其他对冲基金最近也调整了对该公司的持股。合并银行在第一季度购买了Talaris治疗公司价值约31,000美元的新股。普罗斯佩拉金融服务公司在第一季度购买了Talaris治疗公司价值约5万美元的新股份。Values First Advisors Inc.在第二季度购买了Talaris治疗公司价值约53,000美元的新股。摩根大通在第一季度将其在Talaris Treateutics股票的持仓量提高了26.3%。摩根大通在此期间增持了3,090股，目前持有14,826股该公司股票，价值14.6万美元。最后，纽约州共同退休基金在第一季度将其在Talaris Treeutics的股票头寸提高了45.2%。纽约州共同退休基金现在拥有14,794股该公司的股票，价值146,000美元，在此期间又购买了4,605股。机构投资者持有该公司67.99%的股份。
Talaris Therapeutics Stock Performance
Talaris Treateutics股票表现
Shares of TALS opened at $1.39 on Wednesday. The stock has a fifty day moving average price of $2.18 and a two-hundred day moving average price of $4.29. Talaris Therapeutics, Inc. has a 52-week low of $1.16 and a 52-week high of $16.63. The company has a market cap of $57.99 million, a price-to-earnings ratio of -0.86 and a beta of 1.94.
周三，Tals的股价开盘报1.39美元。该股的50日移动均线价格为2.18美元，200日移动均线价格为4.29美元。Talaris Treateutics，Inc.的52周低点为1.16美元，52周高点为16.63美元。该公司市值为5799万美元，市盈率为-0.86倍，贝塔系数为1.94。
Analyst Ratings Changes
分析师评级发生变化
About Talaris Therapeutics
关于Talaris Treateutics
(Get Rating)
(获取评级)
Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
Talaris治疗公司在美国作为一家临床晚期细胞治疗公司运营。该公司致力于开发异基因造血干细胞移植的方法，以改变实体器官移植和严重的自身免疫性疾病以及严重的非恶性血液、免疫和代谢疾病的护理标准。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick's Sporting Goods
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- 免费获取StockNews.com关于Talaris治疗(TALS)的研究报告
- 在取消了13%的股息后，Lumen Technologies可以拥有吗？
- 思科希望重组削减成本以增加收入
- Dick‘s体育用品的卖方上限收益
- 想要获得10%的股息收益率，看看这里
- 炒股：3只有吸引力的股票，交易价格在10美元左右
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Talaris治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Talaris治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧